MEA Sarcopenia Treatment Market - Industry Trends and Forecast to 2033

List of Tables

The Europe sarcopenia treatment market is expected to reach USD 1,033,968.39 thousand by 2030 from USD 725,593.95 thousand in 2022, growing at a CAGR of 4.6% in the forecast period of 2023 to 2030

Market Segmentation

Europe Sarcopenia Treatment Market, By Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route Of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland, And Rest Of Europe) - Industry Trends and Forecast to 2030.

Overview of Europe Sarcopenia Treatment Market Dynamics:

Driver
Rising prevalence of sarcopenia
Restraint
Lack of standardized diagnosis
Opportunity
Strategic initiatives by key market players

Market Players

Some of the key market players operating in the Europe sarcopenia treatment market are listed below:

Abbott,
Nestle Health Science (A subsidiary of Nestle S.A.)
Novartis AG
Sanofi
Haleon Group of Companies
BASF SE
DSM
Fermenta Biotech Limited
AstaReal Co., Ltd.
Metagenics
Wellona Pharma
The Vitamin Company India
Healing Pharma India Pvt. Ltd
Others

1 INTRODUCTION 26

1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF THE EUROPE SARCOPENIA TREATMENT MARKET 26
1.4 CURRENCY AND PRICING 28
1.5 LIMITATIONS 28
1.6 MARKETS COVERED 28

2 MARKET SEGMENTATION 31

2.1 MARKETS COVERED 31
2.2 GEOGRAPHICAL SCOPE 32
2.3 YEARS CONSIDERED FOR THE STUDY 33
2.4 DBMR TRIPOD DATA VALIDATION MODEL 34
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
2.6 MULTIVARIATE MODELLING 38
2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE 38
2.8 MARKET END USER COVERAGE GRID 39
2.9 DBMR MARKET POSITION GRID 40
2.10 VENDOR SHARE ANALYSIS 42
2.11 SECONDARY SOURCES 43
2.12 ASSUMPTIONS 43

3 EXECUTIVE SUMMARY 44

4 PREMIUM INSIGHTS 47

4.1 PESTEL ANALYSIS 48
4.2 PORTER'S FIVE FORCES MODEL 49
4.3 CURRENT STATUS OF EMERGING DRUGS FOR SARCOPENIA TREATMENT 50

5 EUROPE SARCOPENIA TREATMENT MARKET: REGULATIONS 51

5.1 REGULATIONS IN U.S. 51
5.2 REGULATIONS IN EUROPE 51
5.3 REGULATIONS IN AUSTRALIA 52
5.4 REGULATIONS IN SOUTH AFRICA 52

6 MARKET OVERVIEW 53

6.1 DRIVERS 55
- 6.1.1 RISING PREVALENCE OF SARCOPENIA 55
- 6.1.2 GROWING AWARENESS OF SARCOPENIA AND ITS DETRIMENTAL EFFECTS ON HEALTH 55
- 6.1.3 LIFESTYLE FACTORS SUCH AS POOR NUTRITION AND SEDENTARY BEHAVIOUR 56
6.2 RESTRAINTS 57
- 6.2.1 LACK OF STANDARDIZED DIAGNOSIS 57
- 6.2.2 HIGH COST OF TREATMENT AND INTERVENTIONS 57
6.3 OPPORTUNITIES 58
- 6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 58
- 6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 58
6.4 CHALLENGES 59
- 6.4.1 COMPLICATIONS ASSOCIATED WITH THE SARCOPENIA TREATMENT 59
- 6.4.2 STRINGENT GOVERNMENT RULES AND REGULATION FOR PRODUCT APPROVAL 60

7 EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE 61

7.1 OVERVIEW 62
7.2 VITAMIN/DIETARY SUPPLEMENTS 65
- 7.2.1 VITAMIN SUPPLEMENTS 66
- 7.2.2 PROTEIN SUPPLEMENTS 66
- 7.2.3 FATTY ACID SUPPLEMENTS 66
- 7.2.4 CREATINE 66
- 7.2.5 WHEY PROTEINS 66
- 7.2.6 L-CARNITINE 66
- 7.2.7 SOY 66
- 7.2.8 BETA-ALANINE 66
- 7.2.9 OSTARINE 66
- 7.2.10 COLLAGEN PEPTIDES 66
- 7.2.11 LIGANDROL 67
- 7.2.12 BRANCH-CHAIN AMINO ACIDS 67
- 7.2.13 HYDROXYMETHYLBUTYRATE (HMB) 67
- 7.2.14 MEDIUM CHAIN TRIGLYCERIDES 67
- 7.2.15 OTHERS 67
7.3 MEDICATIONS 67
- 7.3.1 OFF LABEL DRUGS 68
- 7.3.2 EMERGING DRUGS 68
  - 7.3.2.1 ACE INHIBITORS 68
  - 7.3.2.2 APPETITE STIMULANTS 68
  - 7.3.2.3 ORAL ANTIDIABETIC DRUGS 68
  - 7.3.2.4 OTHERS 69
7.4 OTHERS 69

8 EUROPE SARCOPENIA TREATMENT MARKET, BY TYPE 70

8.1 OVERVIEW 71
8.2 PRIMARY SARCOPENIA 74
- 8.2.1 VITAMIN/DIETARY SUPPLEMENTS 74
- 8.2.2 MEDICATIONS 74
- 8.2.3 OTHERS 74
8.3 SECONDARY SARCOPENIA 75
- 8.3.1 VITAMIN/DIETARY SUPPLEMENTS 75
- 8.3.2 MEDICATIONS 75
- 8.3.3 OTHERS 75

9 EUROPE SARCOPENIA TREATMENT MARKET, BY STAGES 76

9.1 OVERVIEW 77
9.2 PRE-SARCOPENIA 80
9.3 SARCOPENIA 80
9.4 SEVERE SARCOPENIA 81

10 EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 82

10.1 OVERVIEW 83
10.2 ORAL 86
10.3 INJECTABLES 86
10.4 OTHERS 87

11 EUROPE SARCOPENIA TREATMENT MARKET, BY GENDER 88

11.1 OVERVIEW 89
11.2 MALE 92
11.3 FEMALE 92

12 EUROPE SARCOPENIA TREATMENT MARKET, BY END USER 93

12.1 OVERVIEW 94
12.2 HOSPITALS 97
- 12.2.1 PUBLIC 97
- 12.2.2 PRIVATE 97
12.3 SPECIALTY CLINICS 98
12.4 HOME HEALTHCARE 98
12.5 OTHERS 99

13 EUROPE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 100

13.1 OVERVIEW 101
13.2 DIRECT TENDER 104
13.3 RETAIL SALES 104
- 13.3.1 HOSPITAL PHARMACIES 105
- 13.3.2 ONLINE PHARMACIES 105
- 13.3.3 OTHERS 105
13.4 OTHERS 105

14 EUROPE SARCOPENIA TREATMENT MARKET, BY REGION 106

14.1 EUROPE 109
- 14.1.1 GERMANY 116
- 14.1.2 FRANCE 122
- 14.1.3 U.K. 128
- 14.1.4 ITALY 134
- 14.1.5 SPAIN 140
- 14.1.6 RUSSIA 146
- 14.1.7 TURKEY 152
- 14.1.8 BELGIUM 158
- 14.1.9 NETHERLANDS 164
- 14.1.10 SWITZERLAND 170
- 14.1.11 DENMARK 176
- 14.1.12 NORWAY 182
- 14.1.13 SWEDEN 188
- 14.1.14 POLAND 194
- 14.1.15 FINLAND 201
- 14.1.16 REST OF EUROPE 207

15 EUROPE SARCOPENIA TREATMENT MARKET, COMPANY LANDSCAPE 208

15.1 COMPANY SHARE ANALYSIS: EUROPE 208

16 SWOT ANALYSIS 209

17 COMPANY PROFILE 210

17.1 ABBOTT 210
- 17.1.1 COMPANY SNAPSHOT 210
- 17.1.2 REVENUE ANALYSIS 210
- 17.1.3 COMPANY SHARE ANALYSIS 211
- 17.1.4 PRODUCT PORTFOLIO 211
- 17.1.5 RECENT DEVELOPMENT 211
17.2 NESTLE HEALTH SCIENCE (A SUBSIDIARY OF NESTLE S.A.) 212
- 17.2.1 COMPANY SNAPSHOT 212
- 17.2.2 REVENUE ANALYSIS 212
- 17.2.3 COMPANY SHARE ANALYSIS 213
- 17.2.4 PRODUCT PORTFOLIO 213
- 17.2.5 RECENT DEVELOPMENT 213
17.3 NOVARTIS AG 214
- 17.3.1 COMPANY SNAPSHOT 214
- 17.3.2 REVENUE ANALYSIS 214
- 17.3.3 COMPANY SHARE ANALYSIS 215
- 17.3.4 PRODUCT PORTFOLIO 215
- 17.3.5 PIPELINE PORTFOLIO 215
- 17.3.6 RECENT DEVELOPMENT 215
17.4 SANOFI 216
- 17.4.1 COMPANY SNAPSHOT 216
- 17.4.2 REVENUE ANALYSIS 216
- 17.4.3 COMPANY SHARE ANALYSIS 217
- 17.4.4 PRODUCT PORTFOLIO 217
- 17.4.5 RECENT DEVELOPMENT 217
17.5 HALEON GROUP OF COMPANIES. 218
- 17.5.1 COMPANY SNAPSHOT 218
- 17.5.2 REVENUE ANALYSIS 218
- 17.5.3 COMPANY SHARE ANALYSIS 219
- 17.5.4 PRODUCT PORTFOLIO 219
- 17.5.5 RECENT DEVELOPMENT 219
17.6 ASTAREAL CO., LTD. 220
- 17.6.1 COMPANY SNAPSHOT 220
- 17.6.2 PRODUCT PORTFOLIO 220
- 17.6.3 RECENT DEVELOPMENT 220
17.7 BASF SE 221
- 17.7.1 COMPANY SNAPSHOT 221
- 17.7.2 REVENUE ANALYSIS 221
- 17.7.3 PRODUCT PORTFOLIO 222
- 17.7.4 RECENT DEVELOPMENT 222
17.8 BIOGEN SA 223
- 17.8.1 COMPANY SNAPSHOT 223
- 17.8.2 PRODUCT PORTFOLIO 223
- 17.8.3 RECENT DEVELOPMENT 223
17.9 BIOTHRIVE SCIENCES 224
- 17.9.1 COMPANY SNAPSHOT 224
- 17.9.2 PRODUCT PORTFOLIO 224
- 17.9.3 RECENT DEVELOPMENT 224
17.10 DSM 225
- 17.10.1 COMPANY SNAPSHOT 225
- 17.10.2 REVENUE ANALYSIS 225
- 17.10.3 PRODUCT PORTFOLIO 226
- 17.10.4 RECENT DEVELOPMENT 226
17.11 FERMENTA BIOTECH LIMITED 227
- 17.11.1 COMPANY SNAPSHOT 227
- 17.11.2 REVENUE ANALYSIS 227
- 17.11.3 PRODUCT PORTFOLIO 228
- 17.11.4 RECENT DEVELOPMENT 228
17.12 HEALING PHARMA INDIA PVT. LTD. 229
- 17.12.1 COMPANY SNAPSHOT 229
- 17.12.2 PRODUCT PORTFOLIO 229
- 17.12.3 RECENT DEVELOPMENT 229
17.13 METAGENICS 230
- 17.13.1 COMPANY SNAPSHOT 230
- 17.13.2 PRODUCT PORTFOLIO 230
- 17.13.3 RECENT DEVELOPMENT 230
17.14 THE VITAMIN COMPANY INDIA 231
- 17.14.1 COMPANY SNAPSHOT 231
- 17.14.2 PRODUCT PORTFOLIO 231
- 17.14.3 RECENT DEVELOPMENT 231
17.15 WELLONA PHARMA 232
- 17.15.1 COMPANY SNAPSHOT 232
- 17.15.2 PRODUCT PORTFOLIO 232
- 17.15.3 RECENT DEVELOPMENT 232
17.16 ARMGO PHARMA, INC. 233
- 17.16.1 COMPANY SNAPSHOT 233
- 17.16.2 PIPELINE PORTFOLIO 233
- 17.16.3 RECENT DEVELOPMENT 233
17.17 BIOPHYTIS 234
- 17.17.1 COMPANY SNAPSHOT 234
- 17.17.2 PIPELINE PORTFOLIO 234
- 17.17.3 RECENT DEVELOPMENT 234
17.18 DYSTROGEN THERAPEUTICS CORP 235
- 17.18.1 COMPANY SNAPSHOT 235
- 17.18.2 PIPELINE PORTFOLIO 235
- 17.18.3 RECENT DEVELOPMENT 235
17.19 IMMUNOFORGE INC. 236
- 17.19.1 COMPANY SNAPSHOT 236
- 17.19.2 PIPELINE PORTFOLIO 236
- 17.19.3 RECENT DEVELOPMENT 236
17.20 MYMD PHARMACEUTICALS 237
- 17.20.1 COMPANY SNAPSHOT 237
- 17.20.2 PIPELINE PORTFOLIO 237
- 17.20.3 RECENT DEVELOPMENT 237
17.21 NMD PHARMA A/S 238
- 17.21.1 COMPANY SNAPSHOT 238
- 17.21.2 PIPELINE PORTFOLIO 238
- 17.21.3 RECENT DEVELOPMENT 238
17.22 ONCOCROSS CO., LTD. 239
- 17.22.1 COMPANY SNAPSHOT 239
- 17.22.2 PIPELINE PORTFOLIO 239
- 17.22.3 RECENT DEVELOPMENT 239
17.23 OPKO HEALTH, INC. 240
- 17.23.1 COMPANY SNAPSHOT 240
- 17.23.2 REVENUE ANALYSIS 240
- 17.23.3 PIPELINE PORTFOLIO 241
- 17.23.4 RECENT DEVELOPMENT 241
17.24 REGENERON PHARMACEUTICALS INC. 242
- 17.24.1 COMPANY SNAPSHOT 242
- 17.24.2 REVENUE ANALYSIS 242
- 17.24.3 PIPELINE PORTFOLIO 243
- 17.24.4 RECENT DEVELOPMENT 243
17.25 REJUVENATE BIOMED NV 244
- 17.25.1 COMPANY SNAPSHOT 244
- 17.25.2 PIPELINE PORTFOLIO 244
- 17.25.3 RECENT DEVELOPMENT 244

18 QUESTIONNAIRE 245

19 RELATED REPORTS 249

LIST OF TABLES

TABLE 1 CURRENT STATUS OF THE DEVELOPMENT OF DRUG FOR SARCOPENIA TREATMENT 50
TABLE 2 EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 64
TABLE 3 EUROPE VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 65
TABLE 4 EUROPE VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 65
TABLE 5 EUROPE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 67
TABLE 6 EUROPE MEDICATINONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 68
TABLE 7 EUROPE OFF-LABLE DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 68
TABLE 8 EUROPE OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 69
TABLE 9 EUROPE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 73
TABLE 10 EUROPE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 74
TABLE 11 EUROPE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 74
TABLE 12 EUROPE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 75
TABLE 13 EUROPE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 75
TABLE 14 EUROPE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 79
TABLE 15 EUROPE PRE-SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 80
TABLE 16 EUROPE SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 80
TABLE 17 EUROPE SEVERE SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 81
TABLE 18 EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 85
TABLE 19 EUROPE ORAL IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 86
TABLE 20 EUROPE INJECTABLES IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 86
TABLE 21 EUROPE OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 87
TABLE 22 EUROPE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 91
TABLE 23 EUROPE MALE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 92
TABLE 24 EUROPE FEMALE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 92
TABLE 25 EUROPE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 96
TABLE 26 EUROPE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 97
TABLE 27 EUROPE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 97
TABLE 28 EUROPE SPECIALTY CLINICS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 98
TABLE 29 EUROPE HOME HEALTHCARE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 98
TABLE 30 EUROPE OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 99
TABLE 31 EUROPE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 103
TABLE 32 EUROPE DIRECT TENDER IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 104
TABLE 33 EUROPE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 104
TABLE 34 EUROPE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 105
TABLE 35 EUROPE OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 105
TABLE 36 EUROPE SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 109
TABLE 37 EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 110
TABLE 38 EUROPE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 110
TABLE 39 EUROPE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 110
TABLE 40 EUROPE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 111
TABLE 41 EUROPE VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 111
TABLE 42 EUROPE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 112
TABLE 43 EUROPE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 112
TABLE 44 EUROPE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 112
TABLE 45 EUROPE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 113
TABLE 46 EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 113
TABLE 47 EUROPE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 113
TABLE 48 EUROPE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 114
TABLE 49 EUROPE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 114
TABLE 50 EUROPE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 114
TABLE 51 EUROPE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 115
TABLE 52 GERMANY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 116
TABLE 53 GERMANY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 116
TABLE 54 GERMANY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 116
TABLE 55 GERMANY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 117
TABLE 56 GERMANY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 117
TABLE 57 GERMANY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 118
TABLE 58 GERMANY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 118
TABLE 59 GERMANY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 60 GERMANY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 61 GERMANY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 119
TABLE 62 GERMANY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 120
TABLE 63 GERMANY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 120
TABLE 64 GERMANY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 120
TABLE 65 GERMANY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 121
TABLE 66 GERMANY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 121
TABLE 67 GERMANY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 121
TABLE 68 FRANCE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 122
TABLE 69 FRANCE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 122
TABLE 70 FRANCE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 122
TABLE 71 FRANCE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 123
TABLE 72 FRANCE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 123
TABLE 73 FRANCE VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 74 FRANCE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 75 FRANCE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 76 FRANCE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 77 FRANCE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 125
TABLE 78 FRANCE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 126
TABLE 79 FRANCE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 126
TABLE 80 FRANCE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 126
TABLE 81 FRANCE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 127
TABLE 82 FRANCE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 127
TABLE 83 FRANCE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 127
TABLE 84 U.K. SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 128
TABLE 85 U.K. MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 128
TABLE 86 U.K. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 128
TABLE 87 U.K. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 129
TABLE 88 U.K. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 129
TABLE 89 U.K. VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 90 U.K. SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 91 U.K. PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 131
TABLE 92 U.K. SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 131
TABLE 93 U.K. SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 131
TABLE 94 U.K. SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 132
TABLE 95 U.K. SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 132
TABLE 96 U.K. SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 132
TABLE 97 U.K. HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 133
TABLE 98 U.K. SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 133
TABLE 99 U.K. RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 133
TABLE 100 ITALY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 101 ITALY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 102 ITALY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 103 ITALY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 135
TABLE 104 ITALY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 135
TABLE 105 ITALY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 136
TABLE 106 ITALY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 136
TABLE 107 ITALY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 137
TABLE 108 ITALY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 137
TABLE 109 ITALY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 137
TABLE 110 ITALY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 138
TABLE 111 ITALY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 138
TABLE 112 ITALY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 138
TABLE 113 ITALY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 114 ITALY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 139
TABLE 115 ITALY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 139
TABLE 116 SPAIN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 117 SPAIN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 118 SPAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 119 SPAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 141
TABLE 120 SPAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 141
TABLE 121 SPAIN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 142
TABLE 122 SPAIN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 142
TABLE 123 SPAIN PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 143
TABLE 124 SPAIN SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 143
TABLE 125 SPAIN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 143
TABLE 126 SPAIN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 144
TABLE 127 SPAIN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 144
TABLE 128 SPAIN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 144
TABLE 129 SPAIN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 145
TABLE 130 SPAIN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 145
TABLE 131 SPAIN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 145
TABLE 132 RUSSIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
TABLE 133 RUSSIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
TABLE 134 RUSSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
TABLE 135 RUSSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 147
TABLE 136 RUSSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 147
TABLE 137 RUSSIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 148
TABLE 138 RUSSIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 148
TABLE 139 RUSSIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 149
TABLE 140 RUSSIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 149
TABLE 141 RUSSIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 149
TABLE 142 RUSSIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 150
TABLE 143 RUSSIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 150
TABLE 144 RUSSIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 150
TABLE 145 RUSSIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 151
TABLE 146 RUSSIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 151
TABLE 147 RUSSIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 151
TABLE 148 TURKEY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 152
TABLE 149 TURKEY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 152
TABLE 150 TURKEY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 152
TABLE 151 TURKEY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 153
TABLE 152 TURKEY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 153
TABLE 153 TURKEY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 154
TABLE 154 TURKEY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 154
TABLE 155 TURKEY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 155
TABLE 156 TURKEY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 155
TABLE 157 TURKEY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 155
TABLE 158 TURKEY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 156
TABLE 159 TURKEY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 156
TABLE 160 TURKEY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 156
TABLE 161 TURKEY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 157
TABLE 162 TURKEY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 157
TABLE 163 TURKEY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 157
TABLE 164 BELGIUM SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 158
TABLE 165 BELGIUM MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 158
TABLE 166 BELGIUM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 158
TABLE 167 BELGIUM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 159
TABLE 168 BELGIUM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 159
TABLE 169 BELGIUM VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 160
TABLE 170 BELGIUM SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 160
TABLE 171 BELGIUM PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 161
TABLE 172 BELGIUM SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 161
TABLE 173 BELGIUM SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 161
TABLE 174 BELGIUM SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 162
TABLE 175 BELGIUM SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 162
TABLE 176 BELGIUM SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 162
TABLE 177 BELGIUM HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 163
TABLE 178 BELGIUM SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 163
TABLE 179 BELGIUM RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 163
TABLE 180 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 164
TABLE 181 NETHERLANDS MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 164
TABLE 182 NETHERLANDS OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 164
TABLE 183 NETHERLANDS OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 165
TABLE 184 NETHERLANDS OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 165
TABLE 185 NETHERLANDS VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 166
TABLE 186 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 166
TABLE 187 NETHERLANDS PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 167
TABLE 188 NETHERLANDS SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 167
TABLE 189 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 167
TABLE 190 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 168
TABLE 191 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 168
TABLE 192 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 168
TABLE 193 NETHERLANDS HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 169
TABLE 194 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 169
TABLE 195 NETHERLANDS RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 169
TABLE 196 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 170
TABLE 197 SWIZTERLAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 170
TABLE 198 SWIZTERLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 170
TABLE 199 SWIZTERLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 171
TABLE 200 SWIZTERLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 171
TABLE 201 SWIZTERLAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 172
TABLE 202 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 172
TABLE 203 SWIZTERLAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 173
TABLE 204 SWIZTERLAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 173
TABLE 205 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 173
TABLE 206 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 174
TABLE 207 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 174
TABLE 208 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 174
TABLE 209 SWIZTERLAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 175

TABLE 210 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 175
TABLE 211 SWIZTERLAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 175
TABLE 212 DENMARK SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 176
TABLE 213 DENMARK MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 176
TABLE 214 DENMARK OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 176
TABLE 215 DENMARK OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 177
TABLE 216 DENMARK OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 177
TABLE 217 DENMARK VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 178
TABLE 218 DENMARK SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 178
TABLE 219 DENMARK PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 179
TABLE 220 DENMARK SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 179
TABLE 221 DENMARK SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 179
TABLE 222 DENMARK SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 180
TABLE 223 DENMARK SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 180
TABLE 224 DENMARK SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 180
TABLE 225 DENMARK HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 181
TABLE 226 DENMARK SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 181
TABLE 227 DENMARK RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 181
TABLE 228 NORWAY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 182
TABLE 229 NORWAY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 182
TABLE 230 NORWAY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 182
TABLE 231 NORWAY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 183
TABLE 232 NORWAY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 183
TABLE 233 NORWAY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 184
TABLE 234 NORWAY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 184
TABLE 235 NORWAY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 185
TABLE 236 NORWAY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 185
TABLE 237 NORWAY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 185
TABLE 238 NORWAY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 186
TABLE 239 NORWAY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 186
TABLE 240 NORWAY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 186
TABLE 241 NORWAY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 187
TABLE 242 NORWAY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 187
TABLE 243 NORWAY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 187
TABLE 244 SWEDEN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 188
TABLE 245 SWEDEN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 188
TABLE 246 SWEDEN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 188
TABLE 247 SWEDEN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 189
TABLE 248 SWEDEN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 189
TABLE 249 SWEDEN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 190
TABLE 250 SWEDEN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 190
TABLE 251 SWEDEN SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 191
TABLE 252 SWEDEN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 191
TABLE 253 SWEDEN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 192
TABLE 254 SWEDEN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 192
TABLE 255 SWEDEN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 192
TABLE 256 SWEDEN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 193
TABLE 257 SWEDEN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 193
TABLE 258 SWEDEN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 193
TABLE 259 POLAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 194
TABLE 260 POLAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 194
TABLE 261 POLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 194
TABLE 262 POLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 195
TABLE 263 POLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 195
TABLE 264 POLAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 196
TABLE 265 POLAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 197
TABLE 266 POLAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 197
TABLE 267 POLAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 197
TABLE 268 POLAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 198
TABLE 269 POLAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 198
TABLE 270 POLAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 198
TABLE 271 POLAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 199
TABLE 272 POLAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 199
TABLE 273 POLAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 199
TABLE 274 POLAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 200
TABLE 275 FINLAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 201
TABLE 276 FINLAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 201
TABLE 277 FINLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 201
TABLE 278 FINLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 202
TABLE 279 FINLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 202
TABLE 280 FINLAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 203
TABLE 281 FINLAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 203
TABLE 282 FINLAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 204
TABLE 283 FINLAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 204
TABLE 284 FINLAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 204
TABLE 285 FINLAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 205
TABLE 286 FINLAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 205
TABLE 287 FINLAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 205
TABLE 288 FINLAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 206
TABLE 289 FINLAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 206
TABLE 290 FINLAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 206
TABLE 291 REST OF EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 207

LIST OF FIGURES

FIGURE 1 EUROPE SARCOPENIA TREATMENT MARKET: SEGMENTATION 31
FIGURE 2 EUROPE SARCOPENIA TREATMENT MARKET: DATA TRIANGULATION 34
FIGURE 3 EUROPE SARCOPENIA TREATMENT MARKET: DROC ANALYSIS 35
FIGURE 4 EUROPE SARCOPENIA TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 36
FIGURE 5 EUROPE SARCOPENIA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 36
FIGURE 6 EUROPE SARCOPENIA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 37
FIGURE 7 EUROPE SARCOPENIA TREATMENT MARKET: MARKET END USERS COVERAGE GRID 39
FIGURE 8 EUROPE SARCOPENIA TREATMENT MARKET: DBMR MARKET POSITION GRID 40
FIGURE 9 EUROPE SARCOPENIA TREATMENT MARKET: VENDOR SHARE ANALYSIS 42
FIGURE 10 EUROPE SARCOPENIA TREATMENT MARKET: SEGMENTATION 46
FIGURE 11 THE RISING PREVALENCE OF SARCOPENIA AND GROWING AWARENESS OF SARCOEPNIA AND ITS DETRIMENTAL EFFECT ON HEALTH ARE EXPECTED TO DRIVE THE GROWTH OF THE EUROPE SARCOPENIA TREATMENT MARKET FROM 2023 TO 2030 47
FIGURE 12 VITAMIN/DIETARY SUPPLEMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PRECLINICAL MARKET IN 2023 AND 2030 47
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE SARCOPENIA TREATMENT MARKET 54
FIGURE 14 EUROPE SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2022 62
FIGURE 15 EUROPE SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND) 63
FIGURE 16 EUROPE SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2023-2030) 63
FIGURE 17 EUROPE SARCOPENIA TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE 64
FIGURE 18 EUROPE SARCOPENIA TREATMENT MARKET: BY TYPE, 2022 71
FIGURE 19 EUROPE SARCOPENIA TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND) 72
FIGURE 20 EUROPE SARCOPENIA TREATMENT MARKET: BY TYPE, CAGR (2023-2030) 72
FIGURE 21 EUROPE SARCOPENIA TREATMENT MARKET: BY TYPE, LIFELINE CURVE 73
FIGURE 22 EUROPE SARCOPENIA TREATMENT MARKET: BY STAGES, 2022 77
FIGURE 23 EUROPE SARCOPENIA TREATMENT MARKET: BY STAGES, 2023-2030 (USD THOUSAND) 78
FIGURE 24 EUROPE SARCOPENIA TREATMENT MARKET: BY STAGES, CAGR (2023-2030) 78
FIGURE 25 EUROPE SARCOPENIA TREATMENT MARKET: BY STAGES, LIFELINE CURVE 79
FIGURE 26 EUROPE SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 83
FIGURE 27 EUROPE SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION (2023-2030) 84
FIGURE 28 EUROPE SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION (2023-2030) 84
FIGURE 29 EUROPE SARCOPENIA TREATMENT MARKET: LIFELINE CURVE 85
FIGURE 30 EUROPE SARCOPENIA TREATMENT MARKET: BY GENDER, 2022 89
FIGURE 31 EUROPE SARCOPENIA TREATMENT MARKET: BY GENDER, 2023-2030 (USD THOUSAND) 90
FIGURE 32 EUROPE SARCOPENIA TREATMENT MARKET: BY GENDER, CAGR (2023-2030) 90
FIGURE 33 EUROPE SARCOPENIA TREATMENT MARKET: BY GENDER, LIFELINE CURVE 91
FIGURE 34 EUROPE SARCOPENIA TREATMENT MARKET: BY END USER, 2022 94
FIGURE 35 EUROPE SARCOPENIA TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 95
FIGURE 36 EUROPE SARCOPENIA TREATMENT MARKET: BY END USER, CAGR (2023-2030) 95
FIGURE 37 EUROPE SARCOPENIA TREATMENT MARKET: BY END USER, LIFELINE CURVE 96
FIGURE 38 EUROPE SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 101
FIGURE 39 EUROPE SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 102
FIGURE 40 EUROPE SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 102
FIGURE 41 EUROPE SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 103
FIGURE 42 EUROPE SARCOPENIA TREATMENT MARKET: SNAPSHOT (2022) 107
FIGURE 43 EUROPE SARCOPENIA TREATMENT MARKETSTRUCTURAL HEALTH MONITORING MARKET: COMPANY SHARE 2022 (%) 208